In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The Belgian antitrust regulator sanctioned some of the largest purveyors of over-the-counter medicines, the latest effort by ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company ...

Novus Diagnostics, an innovator in the field of rapid point-of-care diagnostics, announces the appointment of Dr. Margrit ...

Clarivate Plc , a leading global provider of transformative intelligence, today announced the launch of DRG Commercial Analytics 360?a solution designed to empower medtech companies with advanced ...

The "Enterprise Tech Ecosystem Series: Boehringer Ingelheim 2025" company profile has been added to ResearchAndMarkets.com's offering. Boehringer Ingelheim International: Leading the Way in ...

Suanfarma, a global company specializing in the development, production, and commercialization of active pharmaceutical ...

Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of ...